Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights

Geron posts Q3 profit on strong RYTELO growth and tight cost control.

What the company is saying

Geron Corporation, led by President and CEO Harout Semerjian, frames the quarter as one of strong RYTELO demand growth, emphasizing a 10% sequential increase in demand and an 8% rise in ordering accounts to approximately 1,700. The company highlights RYTELO's $60.1 million net product revenue for Q3 2026 and positions itself as confident in the long-term U.S. commercial opportunity. Geron is actively expanding internationally, with a gated launch in Europe and RYTELO expected to be available in Germany by year-end and in France in 2027. The announcement also spotlights scientific credibility through multiple conference presentations and two peer-reviewed publications on imetelstat, as well as a nomination for the 2026 Prix Galien USA Award. The company attributes its swing to net income primarily to increased revenue and disciplined cost management, specifically lower personnel and clinical development expenses. Geron also discloses the discontinuation of the Phase 3 IMpactMF trial in myelofibrosis due to futility, clarifying that no new safety signals were observed.

What the data suggests

Q3 2026 net product revenue reached $60.1 million, up from $47.2 million in Q3 2025, reflecting strong commercial uptake of RYTELO. Demand grew 10% quarter-over-quarter, and ordering accounts rose 8% to about 1,700, indicating expanding market penetration. The company swung to a net income of $1.4 million ($0.00 per share) from a net loss of $18.4 million ($0.03 per share) a year earlier, driven by higher revenue and reduced operating expenses. Total costs and operating expenses fell to $54.4 million from $61.1 million, with R&D expenses dropping to $12.7 million and SG&A to $35.7 million. Cost of goods sold increased to $6.1 million, mainly due to non-cash inventory expenses. Liquidity strengthened, with cash and equivalents rising to $339.4 million from $326.9 million in the prior quarter. Full-year 2026 guidance remains for RYTELO net product revenue at the mid-to-high end of $220 million to $240 million, and total operating expenses have been revised down to $220 million to $230 million. The company states its cash and expected U.S. revenues are sufficient to fund operations for the foreseeable future. The discontinuation of the IMpactMF trial removes a pipeline risk but does not affect the current commercial trajectory.

Analysis

The announcement's tone is positive but proportionate to the measurable progress disclosed. Geron reports realised, audited financial results: RYTELO net product revenue of $60.1 million for Q3 2026, 10% sequential demand growth, and a swing to net income of $1.4 million from a prior-year loss. Operating expenses and cash position are clearly stated, and guidance for full-year revenue and expenses is updated with supporting data. Forward-looking claims (European launch timing, full-year guidance) are limited and grounded in current operational momentum. There is no evidence of narrative inflation or exaggerated claims; the language is factual and supported by detailed financials. The only forward-looking elements are the European rollout timeline and updated guidance, both of which are standard for a commercial-stage company. No large capital outlay is paired with long-dated, uncertain returns.

Risk flags

• ●The European expansion introduces execution risk, as RYTELO's commercial success outside the U.S. depends on regulatory, reimbursement, and market adoption factors in Germany and France. The timeline for France extends into 2027, making revenue contributions from that market a longer-term prospect.
• ●The discontinuation of the Phase 3 IMpactMF trial in myelofibrosis removes a potential future indication for imetelstat, narrowing the near-term pipeline and concentrating commercial reliance on RYTELO's current indications.
• ●Cost of goods sold increased significantly to $6.1 million from $1.0 million year-over-year, primarily due to non-cash inventory-related expenses. If these costs continue to rise faster than revenue, future margins could be pressured.
• ●While liquidity is robust at $339.4 million, the company is guiding for high annual operating expenses ($220 million to $230 million), which will require sustained revenue growth to maintain profitability.

Bottom line

Geron's Q3 2026 results show a clear turnaround, with revenue growth and disciplined cost management driving a swing to profitability. The company is executing well in the U.S. market, with RYTELO demand and ordering accounts both rising, and maintains a strong cash position. The European launch, starting in Germany by year-end, represents the next phase of growth but brings new execution risks and will take time to impact financials, especially in France where launch is not expected until 2027. The discontinuation of the IMpactMF trial limits near-term pipeline diversification but does not detract from the current commercial momentum. Investors should focus on the sustainability of U.S. growth, the pace and success of the European rollout, and the company's ability to manage costs as it scales. The most important takeaway is that Geron is now profitable on a quarterly basis, but future upside will hinge on international execution and maintaining margin discipline.

Announcement summary

(NASDAQ:GERN) Geron Corporation reported financial results for the third quarter of 2026 and provided recent business highlights. RYTELO net product revenue was $60.1 million in Q3 2026. RYTELO demand grew by 10% in Q3 2026 compared to Q2 2026. The number of ordering accounts increased by approximately 8% in Q3 2026 to about 1,700. Geron initiated a gated commercial launch to bring RYTELO to eligible LR-MDS patients in targeted European markets, with availability in Germany expected by the end of 2026 and in France in 2027. The company exhibited three posters at the SOHO 2026 Annual Meeting, including real-world evidence of imetelstat for LR-MDS and updated analyses from the IMerge and IMbark studies. Geron delivered an oral presentation and a poster at the 88th Annual Meeting of the Japanese Society of Hematology, and provided an oral presentation at the 2026 Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology. RYTELO was nominated for the 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseases. Two manuscripts were published in peer-reviewed journals highlighting imetelstat’s role in LR-MDS and other hematological diseases. Geron announced the discontinuation of the Phase 3 IMpactMF trial evaluating imetelstat in JAK inhibitor R/R myelofibrosis based on a DMC recommendation that the trial was unlikely to meet its primary endpoint; no new safety signals were observed. As of September 30, 2026, Geron had approximately $339.4 million in cash, cash equivalents, restricted cash, and marketable securities, compared to $326.9 million as of June 30, 2026. Net income for Q3 2026 was $1.4 million, or $0.00 per share, compared to a net loss of $18.4 million, or $0.03 per share, for Q3 2025. Total product revenue, net for Q3 2026 was $60.1 million, compared to $47.2 million for Q3 2025. Total costs and operating expenses for Q3 2026 were $54.4 million, compared to $61.1 million for Q3 2025. Cost of goods sold was approximately $6.1 million for Q3 2026, compared to $1.0 million for Q3 2025. Research and development expenses for Q3 2026 were $12.7 million, compared to $21.1 million for Q3 2025. Selling, general and administrative expenses for Q3 2026 were $35.7 million, compared to $39.0 million for Q3 2025. For fiscal year 2026, Geron expects RYTELO net product revenue to be at the mid-to-high end of the $220 million to $240 million range. The company now expects total operating expenses to be between $220 million and $230 million, down from prior guidance of $230 million to $240 million. Geron believes its existing cash and anticipated net revenues from U.S. sales of RYTELO will be sufficient to fund projected operating requirements for the foreseeable future. Geron will host a conference call at 8:00 a.m. ET on November 4, 2026, to discuss business updates and Q3 2026 financial results.

Disagree with this article?